Endocrine oncology

Coexisting RET/Papillary Thyroid Cancer (PTC) and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer

J Clin Endocrinol MetabPublished Retrospective cohort study with mechanistic study

Authors' conclusion

Coexisting RET/PTC and TERT promoter mutation identify PTC as a unique clinical entity with high mortality, providing new implications for genetic-based prognostication and potential therapeutic targeting of RET and MEK guided by RET/PTC and TERT status.

Study context

Population
PTC patients with wild-type (WT) BRAF/RAS, complete clinical follow-up and genetic data; 112 women, 47 men, 4 unknown; median age 46.00 (IQR 33.00–61.00) yearsWT BRAF/RAS of 669 pooled
Participants
163 patients
Exposure
Coexisting RET/PTC and TERT promoter mutation vs neither mutation
  • Neither mutationn = 100reference
  • TERT promoter mutation alonen = 18
  • RET/PTC alonen = 31
  • Bothn = 14
Outcome
Mortality
Follow-up
Median 16.13 (IQR 8.09-27.91) months
Methodological detailspooled data sets (TCGA-THCA, MSK-MetTropism, MSK-IMPACT), comparative genotype cohort analysis
  • Pooled data sets (TCGA-THCA, MSK-MetTropism, MSK-IMPACT)
  • Comparative genotype cohort analysis

Main finding

As reported in the abstract

Each group vs neither mutationHazard ratio (95% CI)
TERT promoter mutation alone
2.469(0.405–14.022)
Both
9.019(2.635–30.870)
RET/PTC alone
HR 3.296e-09 (95% CI 0-inf)

Observational data: associations, not effects.

Further findings

Concurrence index between RET/PTC and TERT promoter mutations

Concurrence index
2.040 (95% CI, 1.110-3.747; P = .023)

BRAF/RAS and TERT promoter mutations

Similar results observed with BRAF/RAS and TERT promoter mutations

Mechanism

RET/PTC used the MAP kinase pathway to upregulate mutated TERT, not WT TERT; targeting RET and MEK suppressed mutated TERT but not WT TERT

Original publication

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer. J Clin Endocrinol Metab. Published 13 May 2024. doi:10.1210/clinem/dgae327

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.